Models of Affective Illness: Chronic Mild Stress in the Rat
Authors:
Open Access
- 9 March 2023
- journal article
- research article
- Published by Wiley in Current Protocols
- Vol. 3 (3) , e712
Abstract
This article describes a chronic mild stress (CMS) model for predicting antidepressant response and investigating mechanisms of antidepressant action in rats. Following exposure to a variety of mild stressors for several weeks, the rats’ behavior is modified in several ways that parallel symptoms of depression. Among these is a substantial reduction in consumption of a 1% sucrose solution, which models the cardinal symptom of major depression, anhedonia. Our standard procedure employs a battery of behavioral tests, comprising weekly assessment of sucrose intake and, at the end of treatment, the elevated plus‐maze and novel object recognition tests to assess the anxiogenic and dyscognitive effects of CMS. Chronic administration of antidepressant drugs reverses the decreased sucrose intake and other behavioral changes in these subjects. Also effective are second‐generation antipsychotics. The CMS model can be employed in discovery programs to identify anti‐anhedonic drugs (e.g., antidepressants and antipsychotics) that act more quickly than existing agents. While most antidepressants require 3 to 5 weeks to normalize behavior, some treatments provide a faster onset of action. For example, the CMS‐induced deficits can be reversed by acute or sub‐chronic application of treatments that act rapidly in depressed patients, such as deep brain stimulation (DBS), ketamine, and scopolamine, as well as several compounds that have yet to be tested in humans but have fast‐onset antidepressant‐like effects in animals, such as the 5‐HT‐1A biased agonists NLX‐101 and GLYX‐13. Application of the CMS model in Wistar‐Kyoto (WKY) rats causes similar behavioral changes to those seen in Wistars, but these are not reversed by antidepressant treatment. However, WKY rats respond to DBS and ketamine, which are effective in patients who are antidepressant non‐responders, establishing CMS in WKY rats as a model of treatment‐resistant depression. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC.Basic Protocol: Induction of chronic mild stress in rats as a model of depression and treatment‐resistant depressionKeywords
Funding Information
- Narodowym Centrum Nauki (2019/35/B/NZ7/00787)
This publication has 31 references indexed in Scilit:
- Neurobiology of chronic mild stress: Parallels to major depressionNeuroscience & Biobehavioral Reviews, 2012
- The neurobiology of anhedonia and other reward-related deficitsTrends in Neurosciences, 2012
- In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depressionProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Poster Session INeuropsychopharmacology, 2010
- Attenuation of chronic mild stress-induced ‘anhedonia’ by asenapine is not associated with a ‘hedonic’ profile in intracranial self-stimulationJournal of Psychopharmacology, 2010
- Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptorsBehavioural Pharmacology, 2006
- Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMSNeuropsychobiology, 2005
- Effects of the novel antidepressant milnacipran in a chronic mild stress model of depressionDrug Development Research, 2004
- Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the RatNeuropsychopharmacology, 2002
- Attenuation of place preference conditioning but not place aversion conditioning by chronic mild stressJournal of Psychopharmacology, 1992